Cendifensine
From Wikipedia, the free encyclopedia
Pharmaceutical compound
| Clinical data | |
|---|---|
| Drug class | Monoamine reuptake inhibitor |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C14H17Cl2NO |
| Molar mass | 286.20 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Cendifensine (INN Tooltip International Nonproprietary Name) is a monoamine reuptake inhibitor (MRI)[1] related to the amphetamines and cathinones which has not been marketed at this time.[2] [3] [4] It was first described by 2013[4] and its INN Tooltip International Nonproprietary Name was proposed in 2024.[2] The drug has been patented by Noema Pharma, which is developing a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) known as NOE-115 for the treatment of vasomotor symptoms as well as for binge-eating disorder and depressive disorders.[5] [6] [7]
See also
[edit ]References
[edit ]- ^ WO 2023/161533A1, Garibaldi G, "Triple uptake inhibitor for the treatment of atypical depression", published 31 August 2023, assigned to Noema Pharma AG
- ^ a b "Proposed INN: List 132 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 38 (4). 2024.
cendifensinum cendifensine (3,4-dichlorophenyl)[(3S)-3-propylpyrrolidin-3-yl]methanone monoamine reuptake inhibitor [...] C14H17Cl2NO 1034048-49-1
- ^ "(3,4-Dichlorophenyl)[(3S)-3-propyl-3-pyrrolidinyl]methanone". Global Substance Registration System (GSRS). National Center for Advancing Translational Sciences (NCATS), U.S. National Institutes of Health. Retrieved 24 February 2025.
- ^ a b CA 2860810A1, Adam JM, Dvorak CA, Fishlock D, Humphreys ER, Iding H, Pfleger C, Rege PD, Shi X, Vitale J, Wang S, Zajac M, "(3,4-dichloro-phenyl)-((s)-3-propyl-pyrrolidin-3-yl)-methanone hydrochloride and manufacturing processes", published 23 April 2013, assigned to F Hoffmann La Roche AG
- ^ "NOE 115". AdisInsight. 21 May 2024. Retrieved 24 February 2025.
- ^ "Delving into the Latest Updates on Noema Pharma AG with Synapse". Synapse. 23 January 2025. Retrieved 24 February 2025.
- ^ "Noema Pharma". Noema Pharma. 18 June 2021. Retrieved 24 February 2025.
Stub icon
This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.